Following the announcement that Clarity Pharmaceuticals’ SECuRE trial advanced to a multidose phase, the first patients in cohort 4 received 67Cu-SAR-bisPSMA at 12 GBq. The trial is investigating the potential of 64Cu/67Cu-SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer (mCRPC). ...